In Vitro Diagnostics (IVD) Market to Reach US$ 10 Billion by 2021 In Vitro Diagnostics Market China Report 2021 | Page 2

In Vitro Diagnostics Industry: China Market Size, Share, Trends, Volume and
2021 Forecasts Report
In–Vitro Diagnostics (IVD) Market in China has been growing rapidly in the past few years and is expected
to grow steadily in the next few years, with major growth potential in segments such as infectious disease
testing, chronic disease testing and diagnosis in early stages of disease. Some of the major factors driving
the growth of this market are the rising incidences of chronic lifestyle diseases, public health awareness,
growing aging population, demand of tests in rural areas stimulated by the healthcare reform plan,
increasing demand from the middle class for high–end products and an increase in the number of private
hospitals and independent testing laboratories.
However, low reimbursement rate, absence of quality products by the local companies, population factors
and foreign companies faces difficulty to enter the low end IVD products market are restraining the growth
of this market.
Key Companies Covered in the Report are as follows: Mindray Medical International Limited, Shanghai
Fosun Pharmaceutical Group, Mingyuan Medicare, Da An Gene Co. Ltd., Shanghai Kehua Bio–Engineering
Co. Ltd., Zhejiang D.a. Diagnostics Technology Co., Ltd, ADICON Clinical Laboratories, Guangzhou Kingmed
Diagnostics Center Co. Ltd., Kindstar Global, BGI – Shenzhen, OriGene Technologies.
Immunoassay has emerged as a significant rapidly growing market segment in China IVD market.
Immunoassay test controls nearly XX% market share by the year 2021. Other segments such as Clinical
Chemistry, Molecular testing and POCT are poised to be remarkable expansion in the near future. Growing
demand for infectious disease testing, chronic disease testing and diagnosis in early stages of disease will
usher the China IVD market.
Complete report available at http://www.marketreportsonline.com/496440.html